



Business Results for the First Six Months of the Fiscal Year Ending March 31, 2012

Sysmex Corporation

Hisashi Ietsugu, President and CEO

November 8, 2011

Contents

Chapter 1 Financial Highlights for the First Six Months of the Fiscal Year Ending March 31, 2012

Chapter 2 Consolidated Earnings Forecast for the Fiscal Year Ending March 31, 2012


Forward-Looking Statements

This material contains forward-looking statements about Sysmex Corporation and its Group companies (the Sysmex Group). These forward-looking statements are based on the current judgments and assumptions of the Sysmex Group in light of the information currently available to it. Uncertainties inherent in such judgments and assumptions, the future course of our business operations, and changes in the operating environment both in Japan and overseas may cause our actual results, performance, achievements, or financial position to be materially different from any future results, performance, achievements, or financial position either expressed or implied within these forward-looking statements.

Chapter 1

Financial Highlights for the First Six Months of the Fiscal Year Ending March 31, 2012

Financial Highlights



(First six months of fiscal years to March 31)

(Billions of yen)

	2012 1H		Earlier Forecast		2011 1H		YoY (Previous period = 100%)
		Ratio	(As of May)	Ratio		Ratio	
Net Sales	65.2	100%	65.0	100%	60.0	100%	108.7%
Cost of Sales	24.0	36.9%	-	-	21.0	35.0%	114.5%
SG&A	31.7	48.7%	-	-	29.4	49.1%	107.7%
Operating Income	9.4	14.5%	9.8	15.1%	9.5	15.9%	98.8%
Ordinary Income	8.8	13.6%	10.0	15.4%	8.9	14.9%	99.0%
Net Income	5.8	9.0%	6.1	9.4%	5.5	9.2%	106.6%

● Despite significant yen appreciation, sales increased in Japan and overseas.

● Operating income:

The ratio of cost of sales worsened because of the impact of yen appreciation, but owing to the curtailment of SG&A expenses, the decrease in operating income was slight.

● Non-operating balance: The forex loss was ¥0.78 billion

(Yen) (¥0.7 billion in the previous first half).

➤ Yen appreciation reduced net sales ¥2.0 billion, operating income ¥1.7 billion.

Note: At the exchange rates prevailing one year earlier, net sales would have been up 12.1%, and operating income up 16.6%.

Capital expenditure: ¥3.1 billion
 Depreciation and amortization: ¥3.5 billion
 R&D expenditure: ¥5.8 billion

	2012 1H	Earlier Forecast (as of May)	2011 1H
1USD	79.8	85	89.0
1EUR	113.8	115	113.8


Breakdown of Net Sales and Operating Income




(Billions of yen)

Net Sales

Note: FX impact excluded from regional sales below



Operating Income



Breakdown of Assets and Liabilities/Equity



(Billions of yen)


Assets

Liabilities/Equity

Fixed assets
Current assets


Down
¥0.3
billion

Up
¥0.2
billion



Equity
Up
¥1.1
billion


Liabilities
Down
¥1.2
billion



Consolidated Cash Flows



(Billions of yen)



(First six months of fiscal years to March 31)

* The increase/decrease in cash and cash equivalents includes translation differences on cash and cash deposits.

Topics (1)

- Launched new products in the hematology and non-hematology fields

- Hematology

- Commenced sales of the flagship XN Series (Japan, Europe)
- Began sales in China of the XS500i (five-type analyzer), tailored to emerging market needs, with gradual rollout into other emerging markets

- Hemostasis

- Launched the CS-5100, the top-end model in the CS Series of coagulation analyzers

- Clinical chemistry

- Commenced sales in China and other parts of Asia of JCA-BM6010/C (JEOL) automated clinical chemistry analyzer



Fully automated
coagulation analyzer
CS-5100

- Received Good Design Award 2011 for *in vitro* diagnostic system employing Silent Design®

- Established subsidiary in Russia, a market slated for expansion

- Converted company in Taiwan to wholly owned subsidiary and reinforced sales and support services

- Established subsidiary in the Philippines and commenced direct sales and support in the Manila metro area



Topics (2)

- Sysmex reference counter* was selected by Beijing Institute of Metrology and Testing as the national standard for blood cell counting in China.
- Sysmex 14th Scientific Seminar in China in Xiamen, Fujian Province, attended by approximately 900 people
 - Provided up-to-date information related to healthcare and clinical testing to doctors, nurses, laboratory technicians and other participants in China
- Received Japan Investor Relations Association's Fiscal 2011 Best IR Award
 - The third receipt of this award, following the Fiscal 2004 Best IR Award for Small and Medium-Sized Companies and the Fiscal 2006 Best IR Award



Reference counter



14th Scientific Seminar in China



* Reference counter: A semi-automated instrument used for determining values for blood cell counts (number of red and white blood cells), considered the pinnacle of traceability in hematology.

Net Sales by Geographic Region



Net Sales by Geographic Region (Sales to Customers)

(First six months of fiscal years to March 31)

(Billions of yen)

		2012 1H		2011 1H		YoY (Previous period = 100%)	
			Ratio		Ratio	(Yen)	(Local currency)
Net Sales		65.2	100%	60.0	100%	108.7%	—
Region	Americas	12.6	19.4%	12.4	20.6%	102.3%	114.1%
	Europe	18.3	28.2%	16.8	28.1%	108.8%	108.9%
	China	10.0	15.4%	7.7	13.0%	128.9%	136.7%
	AP	3.3	5.1%	3.2	5.4%	102.7%	102.6%
	Japan*	20.8	31.9%	19.7	32.9%	105.5%	-

* Includes South Korea, Taiwan, other countries and IDEXX

Exchange Rates



(First six months of fiscal years to March 31)

(Yen)

	2012 1H	2011 1H
1USD	79.8	89.0
1EUR	113.8	113.8
1CNY	12.3	13.1
1SGD	64.8	64.7

Note: Assumed exchange rates for fiscal year ending March 31, 2012: 1USD = ¥85 1EUR = ¥115
(As of May 2011 announcement)

Geographic Segment Information: Americas



* Revision in intragroup transaction prices

	(First six months of fiscal years to March 31)		(Billions of yen)
	2012 1H	2011 1H	YoY (Previous period = 100%)
Net Sales	12.6	12.4	102.3%
Operating Income	1.2	1.4	84.8%



Note: On a local currency basis: net sales 114.1%; operating income 94.5%

- Sales were robust in the hematology field, with higher sales offsetting the negative effects of yen appreciation.
 - North America: Sales in the hematology field were strong, owing to sales to IHNs*1 and the VISN*2.
 - Canada: Sales rose, owing to win of large government project.
 - Brazil: Sales of system products were robust.
 - Mexico: Project bids recovered, owing to economic rebound, prompting a sales increase.
- Income decreased, owing to a revision in intragroup transaction prices, the negative effects of substantial yen appreciation and higher SG&A expenses.

*1 IHN: Integrated Healthcare Network

*2 VISN: U.S. Veterans Integrated Service Network

Geographic Segment Information: Europe





(First six months of fiscal years to March 31)

	2012 1H	2011 1H	(Billions of yen) YoY (Previous period = 100%)
Net Sales	18.3	16.8	108.8%
Operating Income	2.7	2.5	104.4%

Note: On a local currency basis: net sales 108.9%; operating income 104.4%

- Sales were affected to some extent by the economic deceleration in Europe, but hematology sales were robust, centering on major countries, resulting in a sales increase.
 - Germany: Sales rose, owing to the acquisition of a large project from a prominent commercial lab.
 - UK, France: We continued to propose systems, and sales increased for both instruments and reagents.
 - Spain: Sales decreased slightly, stemming from budget delays at government-affiliated hospitals.
 - Eastern Europe, Russia: Sales rose substantially, owing to acquisition of project through bid in Russia.
 - Life Sciences: Promoted introduction of instruments, centered on Spain and Italy.
- Operating income increased, owing to the effect of higher sales, overcoming the effect of higher SG&A expenses resulting from such factors as strengthened sales and support structures and the acquisition of Hyphen.

Geographic Segment Information: China



* Revision in intragroup transaction prices



(First six months of fiscal years to March 31)

	2012 1H	2011 1H	YoY (Previous period = 100%)
Net Sales	10.0	7.7	128.9%
Operating Income	1.5	1.4	105.5%

Note: On a local currency basis: net sales 136.7%; operating income 111.9%

- Owing to expansion in healthcare demand, sales in the hematology and non-hematology fields continued to grow substantially.
 - Hematology: Owing to introduction of the XS-500i, sales rose significantly, centering on five-type analyzers.
 - Urinalysis: Sales of urinalysis transport system products were favorable, and sales of instruments and reagents both increased.
 - Hemostasis: Sales of instruments and reagents both increased, in line with growing demand for coagulation and fibrin analysis.
 - Clinical chemistry: Sales grew, owing to introduction of new JCA-BM6010/C (JEOL)
- Operating income increased slightly, owing to changes in intragroup transaction prices and effects of substantial yen appreciation.

Geographic Segment Information: AP




* Revision in intragroup transaction prices

	(First six months of fiscal years to March 31)		(Billions of yen)
	2012 1H	2011 1H	YoY (Previous period = 100%)
Net Sales	3.3	3.2	102.7%
Operating Income	0.08	0.41	19.7%

Note: On a local currency basis: net sales 102.6%; operating income 19.8%

- Sales were up slightly, as sales in the hematology field increased, centered on India, while sales in Indonesia and Australia were down.
 - India: Hematology instrument sales expanded
 - Malaysia: Major orders in the preceding fiscal year pushed up reagent sales.
 - Indonesia: Sales decreased, owing to decline in government bidding projects.
- Operating income declined, as revision in intragroup transaction prices caused the cost ratio to worsen and SG&A expenses increased.

Geographic Segment Information: Japan



Intra-area Transfers: Exports to Group Affiliates
 Sales to Customers: South Korea, Taiwan, other countries and IDEXX
 Sales to Customers: Japan
 Operating Income

* Revision in intragroup transaction prices

(First six months of fiscal years to March 31) (Billions of yen)

	2012 1H	2011 1H	YoY (Previous period = 100%)
Net Sales	41.1	36.7	112.0%
Sales to Customers	20.8	19.7	105.5%
Japan	18.9	18.3	103.0%
South Korea, Taiwan, IDEXX, and other countries	1.9	1.3	138.1%
Intra-Area Transfers	20.3	17.0	119.5%
Operating Income	5.2	3.7	140.3%

- Japan: Continued to promote solution proposals, resulting in sales increase.
- IDEXX Laboratories: Sales of hematology analyzers for animals were favorable.
- Operating income increased, owing to higher sales in Japan and to Group affiliates (overseas) and changes in intragroup transaction prices.

Chapter 2

Consolidated Earnings Forecast for the Fiscal Year Ending March 31, 2012

Consolidated Earnings Forecast

(Revised subsequent to May 2011 announcement)



Consolidated Earnings Forecast for the Year Ending March 31, 2012

● Net Sales: **¥134.0 billion** ● Operating Income: **¥18.5 billion** ● Ordinary Income: **¥18.0 billion** ● Net Income: **¥11.5 billion**
 ● Operating Margin: **13.8%** ● Ordinary Margin: **13.4%** ● Net Income Margin: **8.6%**

Planned Investment

● Capital Expenditure: **¥9.8 billion** ● Depreciation and Amortization: **¥7.3 billion** ● R&D Expenditure: **¥13.3 billion**

Assumed exchange rates for second half:

1USD = ¥76

1EUR = ¥105

Assumed exchange rates for full fiscal year:

1USD = ¥77.9

1EUR = ¥109.4

Note: Assumptions at beginning of year:

1USD = ¥85


1EUR = ¥115

Exchange rates in fiscal year ended March 31, 2011

1USD = ¥85.7






1EUR = ¥113.1

(Billions of yen)



Financial Targets: Sales and Operating Income by Region

(Revised subsequent to May 2011 announcement)



- Intra-area Transfers: Exports to Group Affiliates, others
- Sales to Customers: South Korea, other countries and IDEXX
- Sales to Customers: Japan
- Operating Income

We Believe the Possibilities.

Sysmex Corporation

Contact:

IR & Corporate Communication Dept.

Phone: +81-78-265-0500

Email: info@sysmex.co.jp

www.sysmex.co.jp

Kobe Marathon and Women's Ekiden Race

- Special sponsor of the Kobe Marathon
 - Date: Sunday, November 20, 2011
 - Races: Marathon, quarter marathon
 - Participants: Around 28,000 entrants



- Sysmex Women's Track & Field Team wins second place at the 2011 West Japan Women's Industry Group Ekiden Race (held October 23)

- Qualifying for 31st All Japan's Women's Ekiden Race of the Athletics Federation of Japanese Industry Groups (December 8)



Mizuki Noguchi

Sysmex Corporation